Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
→ Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad)

Will the Biotech sector sustain its momentum in 2024?

Ryan Hasson
Written by Ryan Hasson | Reviewed by Don Miller
January 4, 2024

Key Points

  • Biotech's iShares ETF (IBB) experienced a near 4% upswing on the year's first trading day, outshining struggling sectors.
  • The IBB ETF now faces critical resistance at $138 after a robust three-month climb.
  • AMGN, VRTX, and GILD, the top holdings in the ETF, significantly impact the sector's direction based on their individual performances.
  • 5 stocks we like better than iShares Biotechnology ETF.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Upgrade below.

Upgrade Now See Benefits

Should you invest $1,000 in iShares Biotechnology ETF right now?

Before you consider iShares Biotechnology ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iShares Biotechnology ETF wasn't on the list.

While iShares Biotechnology ETF currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Learn More about Ryan Hasson
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Amgen (AMGN)
4.3613 of 5 stars		$328.35+2.3%2.74%56.51Moderate Buy$326.30
Gilead Sciences (GILD)
4.9234 of 5 stars		$84.95+0.3%3.63%103.60Moderate Buy$84.83
Vertex Pharmaceuticals (VRTX)
4.1206 of 5 stars		$481.71+1.2%N/A-237.30Hold$486.95
iShares Biotechnology ETF (IBB)N/A$145.59+1.7%0.31%N/AN/AN/A
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

Central Garden & Pet: Niche Focus, Big Growth Potential
Evolv Technologies Stock Up 59%: AI Security & 12-Month Forecast
Housing Prices Soar: These 3 Home Stocks May Benefit

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines